SB 422 requires Montana health insurers to cover FDA-approved drugs for advanced or metastatic cancer without forcing patients to first fail other treatments. It prohibits insurers from demanding that patients prove they've tried and failed alternative drugs before approving coverage for new treatments that align with national cancer guidelines. This directly affects patients diagnosed with advanced or metastatic cancer in Montana, ensuring faster access to potentially life-saving medications without unnecessary bureaucratic hurdles. The law applies only to drugs approved by the FDA and consistent with evidence-based cancer treatment protocols.
SB 244 requires all health insurance plans sold in Montana to cover behavioral health screenings and assessments at no cost to the insured. This applies to state employee health plans, disability insurance, health maintenance organizations (HMOs), and self-funded workplace plans. Screenings must use standardized, evidence-based tools, but are optional - insured individuals must actively request them. The bill amends Montana insurance codes to include these coverage requirements, ensuring people can access mental health screenings without out-of-pocket costs when they choose to participate.
SB 136 amends Montana's criminal code (Section 45-2-211, MCA) to state that a patient's consent to physician aid in dying is not a defense to a homicide charge against the physician. The bill defines "physician aid in dying" as a physician prescribing a lethal medication for the patient to self-administer, excluding standard comfort care or withholding life-sustaining treatment. This directly affects physicians who provide such aid, making their actions prosecutable as homicide if consent is claimed as a defense. The law takes effect July 1, 2025, and does not impact existing practices of comfort care or end-of-life treatment under Montana law.
SB 474 would have expanded school immunization exemptions in Montana to include religious exemptions and a new "personal medical informed consent" exemption requiring only a notarized statement. This new exemption would allow students to decline vaccines after consulting a healthcare provider (without needing a provider's signature), distinct from the existing medical exemption requiring a healthcare provider's written statement. The bill also amended school immunization laws (20-5-405 and 49-2-312) to prevent schools from being sued for injuries related to exempt students and to block overly burdensome exemption forms. The bill died in committee on May 23, 2025, and never became law.
SB 164 amends Montana's endangering the welfare of children law to prohibit specific medical treatments for children under 16. The bill bans surgical procedures, puberty blockers, and hormone therapies (like estrogen or testosterone) when used to alter a child's appearance or affirm a gender identity inconsistent with their biological sex. Violating this prohibition is classified as a felony, carrying up to five years in prison and a $10,000 fine, with harsher penalties if the child suffers serious injury. The law would take effect on January 1, 2026, directly affecting medical providers, caregivers, and children under 16 who might receive these treatments.
SB 112 would prohibit Montana state funds (including federal funds) from purchasing opioid reversal drugs after June 30, 2025, from companies involved in opioid settlement agreements. It allows existing contracts for these drugs to continue until fulfillment but bans renewal after the deadline, and requires continued supply under settlement agreements signed before September 1, 2024. The bill directly affects state agencies purchasing opioid reversal medications and pharmaceutical companies that settled opioid-related lawsuits. The bill died in committee in May 2025 and did not become law.
HB 185 directs the Department of Public Health and Human Services (DPHHS) to implement continuous eligibility for children under six years old in the Healthy Montana Kids plan. This means eligible children would remain enrolled in the program until their sixth birthday, regardless of changes in family income or other circumstances that might otherwise make them ineligible. DPHHS is required to apply for the necessary federal waivers and state plan amendments by July 1, 2025, and implement the continuous eligibility within six months of federal approval. The bill aims to provide consistent health coverage for young children enrolled in Medicaid and the Children's Health Insurance Program.
HB 929 proposes to revise laws related to chiropractic practitioners in Montana. The bill would establish an optional license endorsement allowing chiropractors who meet specific requirements to prescribe a limited formulary of noncontrolled, nonscheduled drugs. These drugs include items like over-the-counter analgesics, prescription nonsteroidal anti-inflammatory drugs, and muscle relaxants, intended for musculoskeletal treatment and pain. The Board of Chiropractors would be responsible for establishing the educational qualifications, application procedures, and prescribing protocols for this endorsement, for which a fee may be assessed.
HB 364 proposes to update laws concerning student immunizations and exemptions in K-12 schools. It would require school governing authorities to submit written reports on student immunization and exemption data to state and local health departments. These reports must only contain deidentified or aggregate information, ensuring student privacy. The Department of Public Health and Human Services would determine the specific form and schedule for these reports.
HB 947 requires most individual health insurance policies in Montana to cover continuous glucose monitors (CGMs) and their supplies for people diagnosed with type I or type II diabetes when medically necessary, as prescribed by a healthcare provider. The bill prohibits insurers from denying coverage based on diabetes severity or insulin dependence, and bans special deductibles or limits specifically for CGMs - though standard deductibles may still apply. This affects diabetes patients covered by individual disability, health, or membership insurance plans (excluding Medicare supplements, hospital indemnity, or long-term care policies). The law aims to ensure consistent access to these critical blood sugar monitoring tools without discriminatory coverage barriers.